comparemela.com

Latest Breaking News On - Balaxi pharma - Page 3 : comparemela.com

Indices: Stock market update: Nifty IT index falls 0 19%

Balaxi Pharma Share Price, Balaxi Pharma Stock Price, Balaxi Pharmaceuticals Ltd Stock Price, Share Price, Live BSE/NSE, Balaxi Pharmaceuticals Ltd Bids Offers Buy/Sell Balaxi Pharmaceuticals Ltd news & tips, & F&O Quotes, NSE/BSE Forecast News and Live Quotes

Balaxi Pharma Share Price: Find the latest news on Balaxi Pharma Stock Price. Get all the information on Balaxi Pharma with historic price charts for NSE / BSE. Experts & Broker view also get the Balaxi Pharma Ltd. buy/sell tips detailed news, announcements, Forecasts, Analysts, Valuation, Earning forecasts, Estimates, Recommendations, Analysts Ratings, financial report, company information, annual report, balance sheet, profit & loss account, results and more.

Balaxi Pharmaceuticals Limited conducts Groundbreaking Ceremony for its upcoming Rs 85 Cr State-of-the-Art Manufacturing Facility in Hyderabad

Hyderabad (Telangana) [India], December 13 (ANI/NewsVoir): NSE listed Balaxi Pharmaceuticals Limited, a leading IPR branded pharmaceutical company, performed the groundbreaking ceremony of its US-FDA, EU-GMP, WHO-Geneva Compliant Pharmaceutical Formulation Plant at Jadcherla Mandal, Telangana. The company will be investing Rs. 85 crores in the state-of-the-art facility over a period of one year that will enable them to enter European markets as well as enhance margins in current markets. To drive this initiative forward, a leading consultant, Spectrum Pharmatech Consultant Private Limited has been appointed for the smooth and time bound project execution. Spectrum Pharmatech Pvt. Ltd., Mumbai is the Design, Engineering, and Turnkey Execution Consultant for this project. The plant will provide direct and indirect employment to approximately 350+ individuals. This US-FDA, EU-GMP, WHO-Geneva Compliant Pharmaceutical Formulation facility is housed across approximately 1,50,000 square feet,

Balaxi Pharma posts PAT of Rs 381 million for FY21

Balaxi Pharma posts PAT of Rs 381 million for FY21 Balaxi Pharma posts PAT of Rs 381 million for FY21 25 May 2021 | News Registers EBITDA of Rs 100 million for Q4FY21 Balaxi Pharmaceuticals (Balaxi), a branded IPR-based pharmaceutical company headquartered in Hyderabad, reported its results for the quarter and year ended March 31, 2021. The company recorded a revenue of Rs 530 million for Q4F21, the drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday. EBITDA of Rs 100 million for Q4FY21; EBITDA margin stood at 18.9 per cent. Reported PAT of Rs 84 million for Q4FY21. 

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.